Danske Bank, the largest lender in Denmark, reports better-than-expected lending income in the second quarter as brisker demand for loans offset the impact of lower deposit margins https://t.co/D3S7si2j05 ...

Financial Performance - Realkredit Danmark reported a net profit of DKK 2,455 million for the first half of 2025, an increase from DKK 2,129 million in the same period of 2024, primarily driven by a net reversal of loan impairment charges and lower expenses [5][6][9] - Total expenses decreased to DKK 425 million in H1 2025 from DKK 511 million in H1 2024, attributed to the discontinuation of payments to the fully funded Resolution Fund and reductions in operating expenses [6][9] Loan and Credit Quality - The underlying credit quality remained strong, with loan impairment charges reflecting a net reversal of DKK 129 million in H1 2025, compared to a charge of DKK 227 million in H1 2024 [9] - The average loan-to-value ratio decreased to 50% at the end of June 2025 from 53% at the end of 2024, supported by stable market values and increasing house prices [9] Market Outlook and Initiatives - The outlook for the housing market in Denmark is positive, bolstered by strong macroeconomic indicators and lower inflation, with a notable increase in commercial lending activity [5][6] - Realkredit Danmark and Danske Bank launched initiatives in home finance, including the Danske BoligStart concept aimed at young home finance customers, and removed additional margins on new loans with interest-only periods for lower loan-to-value ratios [2][3] - The company is enhancing digital solutions, including a new housing universe in Danske Mobile Banking, to provide customers with better access to home finance information and services [4][9] Green Financing - There has been a consistent increase in demand for green financing, with total lending across green loan types reaching DKK 30 billion by the end of H1 2025 [9] - The company expanded the purposes for loans for energy improvements, allowing personal customers to borrow at favorable rates for installing battery solutions for surplus electricity [9]

Press release Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 45 14 14 00 Good customer activity and strong credit quality led to solid results for the first half of 2025 Net profit of DKK 11.2 billion Carsten Egeriis, Chief Executive Officer, comments on the financial results: "In the first half-year, we continued our robust performance and delivered solid results in line with our expectations. We saw new business customer relations being established, a continued uplift in lending and a steady ...

Core Viewpoint - Danske Bank has initiated a share buy-back program totaling DKK 5 billion, aiming to repurchase up to 45 million shares from February 10, 2025, to January 30, 2026 [1][2]. Group 1: Share Buy-Back Program Details - The share buy-back program is compliant with the Market Abuse Regulation and Safe Harbour Rules [2]. - As of the last announcement, Danske Bank has repurchased a total of 7,767,490 shares, with a gross value of DKK 1,804,461,787 and a volume-weighted average price (VWAP) of DKK 232.3095 [3]. - In week 27, the bank repurchased an additional 272,290 shares at a VWAP of DKK 257.8509, totaling a gross value of DKK 70,210,229 [3]. Group 2: Accumulated Share Information - The total number of shares repurchased under the program now stands at 8,039,780, representing 0.963% of Danske Bank's share capital [4].

Group 1 - Danske Bank announced a share buy-back programme totaling DKK 5 billion, with a maximum of 45,000,000 shares, running from 10 February 2025 to 30 January 2026 [1] - The share buy-back programme is conducted in compliance with the Market Abuse Regulation and Safe Harbour Rules [2] - In week 26, Danske Bank repurchased a total of 517,152 shares at an average price of DKK 256.4731, with a gross value of DKK 132,635,585 [3] - The total number of shares repurchased under the programme has reached 7,767,490, representing 0.930% of Danske Bank's share capital [4]

Core Points - Danske Bank has initiated a share buy-back programme totaling DKK 5 billion, with a maximum of 45 million shares to be repurchased from February 10, 2025, to January 30, 2026 [1][2] - The programme is conducted in compliance with the Market Abuse Regulation and the Safe Harbour Rules [2] - In week 25, a total of 344,495 shares were repurchased at an average price of DKK 256.4244, amounting to a gross value of DKK 88,336,932 [3][4] - Cumulatively, 7,250,338 shares have been repurchased under the programme, representing 0.868% of Danske Bank's share capital [4]

Core Points - Danske Bank has initiated a share buy-back programme totaling DKK 5 billion, with a maximum of 45 million shares to be repurchased from February 10, 2025, to January 30, 2026 [1][2] - The programme is compliant with the Market Abuse Regulation and the Safe Harbour Rules [2] - In week 24, a total of 228,941 shares were repurchased at an average price of DKK 258.3836, amounting to a gross value of DKK 59,154,595 [3][4] - The total number of shares repurchased under the programme has reached 6,905,843, representing 0.821% of Danske Bank's share capital [4]

Core Points - Danske Bank announced a share buy-back programme totaling DKK 5 billion, with a maximum of 45,000,000 shares, running from 10 February 2025 to 30 January 2026 [1] - The programme is conducted in compliance with the Market Abuse Regulation and Safe Harbour Rules [2] Transactions Summary - In week 23, a total of 199,641 shares were repurchased at an average price of DKK 257.4200, amounting to a gross value of DKK 51,391,583 [3][4] - Cumulatively, as of the last announcement, Danske Bank has repurchased 6,676,902 shares under the buy-back programme, representing 0.794% of its share capital [4]

Group 1 - Danske Bank announced a share buy-back programme totaling DKK 5 billion, with a maximum of 45,000,000 shares, running from 10 February 2025 to 30 January 2026 [1] - The share buy-back programme is conducted in compliance with the Market Abuse Regulation and Safe Harbour Rules [2] - In week 20, Danske Bank repurchased a total of 249,390 shares at an average price of DKK 249.3669, amounting to a gross value of DKK 62,189,608 [3][4] Group 2 - The total number of shares repurchased under the programme has reached 6,021,965, representing 0.721% of Danske Bank's share capital [4]

Core Points - Pharma Equity Group A/S held its Annual General Meeting on April 16, 2025, where various proposals were discussed and adopted [1][6] Group 1: Board of Directors' Report - The former CEO, Thomas Kaas Selsø, presented the Board's report on the Company's activities over the past year, addressing shareholder questions regarding the Market Maker agreement with Danske Bank and the potential delisting from Nasdaq Copenhagen [3][4] - Shareholders expressed concerns about the declining share price, attributing it to large shareholders selling their shares, while also acknowledging the Company's successful financing in 2024 and positive research results [4][5] Group 2: Financial Proposals - The audited 2023 annual report was presented, and the discharge of the Board and Executive Management was proposed, with no objections raised from shareholders [8][11] - The expected revenue for the current financial year was projected at DKK 11 million, based on valuations prepared by Baker Tilly and reviewed by Danske Bank [9] - Outstanding convertible loans were confirmed to total approximately DKK 13 million [10] Group 3: Remuneration and Board Elections - The remuneration for the Board of Directors for the 2025 financial year was proposed, with the Chairman receiving DKK 350,000 and Board members receiving DKK 150,000 [14] - All current Board members were re-elected, and two new members, Troels Peter Troelsen and Charlotte Pahl, were elected [16][17] - BDO Statsautoriseret Revisionsaktieselskab was re-elected as the Company's auditor [18] Group 4: Proposals and Authorizations - Three proposals from the Board were discussed, requiring different majorities for adoption, and all were approved without objections [19][20] - The chairman was authorized to file the adopted resolutions with the Danish Business Authority [21] Group 5: Company Overview - Pharma Equity Group A/S is dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S, with a focus on healthcare and innovative medical solutions [23][24]